BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos 10.3892/br.2016.728 BR-0-0-728 Articles Detection of human papillomavirus DNA in gastric carcinoma specimens in a high-risk region of Iran FakhraeiFarzaneh 1 HaghshenasMohammad Reza 1 HosseiniVahid 2 RafieiAlireza 1 NaghshvarFarshad 1 Alizadeh-NavaeiReza 3 Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48178-44718, Iran Gastrointestinal and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48178-44718, Iran Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran 48178-44718, Iran Correspondence to: Dr Mohammad Reza Haghshenas, Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Km 17 Khazarabad Road, Sari, Mazandaran 48178-44718, Iran, E-mail: haghshenas2001@yahoo.com 09 2016 29 07 2016 5 3 371 375 30032016 07072016 Copyright © 2016, Spandidos Publications 2016

Gastric cancer is the fourth most common type of cancer worldwide and is associated with high mortality rates. The incidence of gastric cancer varies widely in different geographical regions. For example, in Iran, the most northern and northwestern regions are considered to be high-risk areas for gastric cancer. The aim of the present study was to determine the distribution of human papillomavirus (HPV) genotypes among patients with gastric carcinoma in Mazandaran province, Northern Iran, which is a high-risk area. A total of 100 paraffin-embedded tissue samples were obtained from 70 males and 30 females with gastric carcinoma, diagnosed between 2006 and 2013, in the Imam Khomeini Hospital (Sari, Iran). GP5+/GP6+ general primers were applied for detection of HPV DNA in the specimens. Positive samples were then selected and high-risk HPV genotyping was performed. The samples were analyzed by polymerase chain reaction and five (5%) samples were identified to be positive for HPV DNA [four male (5.7%) and one female (3.3%)]. Three (60%) samples were positive for HPV-16, one (20%) sample was positive for HPV-18 and one (20%) sample was positive for HPV-45. Following pathological diagnosis, 88 samples were identified as gastric adenocarcinoma, nine samples were gastric lymphoma, and three samples were gastric and esophagus adenocarcinoma. According to the findings of the present study and the rate of HPV infection in patients with gastric carcinoma, an association between HPV infection and gastric carcinoma in subjects from Northern Iran was not identified.

 gastric carcinoma human papillomavirus HPV genotyping high-risk HPV Introduction

Gastric cancer is one of the most common types of cancer and is a leading cause of cancer-associated mortality in the world (1). Approximately 22,220 patients are diagnosed annually in the United States, of whom 10,990 are expected to succumb to the disease (2). Gastric cancer is more common in men than in women in developed and developing countries (3). Furthermore, the incidence of gastric cancer varies in different geographic regions. Rates are highest in Japan, Korea, China, Chile, Costa Rica and Brazil where the incidence is >20 per 100,000 person-years in men. The intermediate-risk areas are Italy, UK, Germany, the Netherlands and Turkey, and the low-risk areas are USA, Canada, Sweden, Denmark, Egypt, India and Australia (4,5). Comparative studies between Western and Asian countries demonstrate significant differences in the incidence and survival rates of gastric cancer; therefore, ethnicity is a possible risk factor (1). The most important and common cause of gastric cancer is excessive consumption of salt, smoking, long term subjection to nitrosamines in food and drinking water, as well as microbial infections, such as Helicobacter pylori and certain viruses, including the human papillomavirus (HPV) (6,7). Helicobacter pylori causes chronic gastritis and progresses to atrophic gastritis, intestinal metaplasia, glandular dysplasia and eventually gastric carcinoma (8,9).

HPVs are non-enveloped, circular, double-stranded and relatively small DNA tumor viruses with a genome of ~8,000 base pairs (10). These viruses infect cutaneous and mucosal epithelial tissues, which cause a wide variety of diseases from skin and anogenital warts to laryngeal papillomas and anogenital intraepithelial neoplasias, which often progress to malignancy (11). Thus far, >100 different types of HPV have been identified and certain strains of HPV are associated with different risk levels of the transformation into various types of human squamous cell carcinoma (12). HPV is classified into two groups: Mucosal infection HPVs and cutaneous infection HPVs. Each of these groups is divided into high and low risk (12,13). The low-risk HPV types, such as HPV6 and HPV11 commonly cause benign warts and low grade premalignant lesions that regress and do not progress to cancer. The high-risk types of HPV, including HPV-16, −18, −31, −33 and −45 are associated with the development of certain mucosal epithelial cancers, such as cervical, anal, vulvar and penile cancer, as well as oral, laryngeal, esophageal and possibly gastric cancer (14,15). It has been demonstrated that ~20% of oral cancers, particularly oropharyngeal carcinoma in patients who do not use tobacco and alcohol (the most common risk factors) are also at high risk of being HPV-positive (16).

In Iran, the incidence of gastric cancer differs according to the risk level (high, intermediate or low). The northern and northwestern regions are high-risk areas for gastric cancer, whilst other geographical areas are intermediate and low risk. Possible environmental risk factors are proposed as a reason for this variation (5). A strong spatial clustering of gastric cancer in men and women is reported in the Mazandaran province (17). However, there is paucity of information regarding the prevalence of HPV in gastric cancer in the north of Iran and also around the world. The current study was designed to determine the distribution of HPV genotypes among patients with gastric carcinoma in Mazandaran province, northern Iran between 2006 and 2013, using polymerase chain reaction (PCR).

 Materials and methods <sec> <title>Gastric cancer sample collection

A cross-sectional study was performed in which 100 paraffin-embedded tissue samples of gastric cancer were investigated. All samples were from patients that were diagnosed between 2006 and 2013 at the Imam Khomeini Hospital Infection Disease Center (Sari, Iran), which is in Mazandaran province, Northern Iran. The patients included 70 males and 30 females (mean age, 69.61±12.25 years). A questionnaire was used to obtain further information regarding smoking habit, alcohol consumption, weight loss, family history of gastric cancer, anatomical sites of tumors, pathological diagnosis and metastasis.

 Preparation of samples

Sections (thickness, 5–10 µm) were collected in sterile micro tubes. To prevent cross-contamination, sharp blades were used and gloves were changed between each sample cutting. To deparaffinize the samples, the paraffin-embedded tissues were saturated in xylene (30 min), then incubated in a graded ethanol series (1 min each) of 100% ethanol (dehydration) to 40% ethanol, then with double-distilled water for rehydration for 10 sec.

 DNA extraction

DNA extraction was performed using a High Pure PCR Template Preparation kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. In brief, tissue lysis buffer [200 µl; 4 M urea, 200 mM Tris, 20 mM NaCl and 200 mM EDTA (pH 7.4)] and 40 µl proteinase K were mixed and incubated overnight at 37°C. The next day, 200 µl binding buffer [6 M guanidine-HCl, 10 mM urea, 10 mM Tris-HCl, 20% Triton X-100 (v/v); pH 4.4 (25°C)] was added to the tubes and vortexed for a few seconds. To elute the DNA, 200 µl pre-warmed (70°C) elution buffer, low salt (10 mM Tris buffer, pH 8.5; 40 ml) was added and the extracted DNA was stored at −20°C until the PCR. DNA quality and the absence of PCR inhibitors in the samples were evaluated by PCR with β-actin primer serving as a housekeeping gene. Distilled water served as a negative control to monitor contamination during PCR (Table I).

 HPV detection and genotyping

General primers, GP5+ and GP6+, were used to amplify the L1 gene (Table I). PCR was performed using 1X PCR buffer (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 3 mM MgCl2 (Invitrogen; Thermo Fisher Scientific, Inc.), 0.2 mM dNTPs, 0.5 U Taq DNA polymerase (Invitrogen; Thermo Fisher Scientific, Inc.), 25 pmol each primer, 500 ng genomic DNA and sterile distilled water to a final volume of 25 µl. DNA was first denatured for 5 min at 94°C and 40 cycles of the following were performed: Denaturation for 1 min at 94°C, annealing for 1 min at 48°C and elongation for 1 min at 72°C. An additional cycle was also performed for 10 min at 72°C. The HPV positive control was the HeLa cell line (HPV-18 positive). Finally, 10 µl of each PCR product was analyzed by 2% agarose gel electrophoresis (90 V, 30–40 min). A HPV HCR genotype-EPh PCR kit (Amplisens, Voisins-le-Bretonneux, France) was used to determine the HPV genotype in positive samples. A total of 12 high-risk HPV genotypes, specifically 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59 and 66, were examined. PCR amplification for detection of the 12 HPV genotypes was run in three tubes. HPV-positive and -negative samples were included for each sample that was run.

 Gel electrophoresis

To determine the HPV genotypes, PCR products were examined by 1.5% agarose gel electrophoresis. All of the amplified products were different lengths, therefore, genotypes of the virus were analyzed by electrophoresis and visualized by an ultraviolet light trans-illuminator. Bands of appropriate size were identified by comparison with DNA molecular weight markers, which are a set of known DNA fragments. The adequacy of the DNA in each specimen for PCR amplification was determined by detection of the β-actin gene.

 Statistical analysis

The χ2 test and Fisher's exact test were performed to determine the association between the presence of HPV DNA and smoking habit, alcohol consumption, weight loss, family history, anatomical site of tumor, pathological diagnosis, and metastasis. SPSS software (version 14; SPSS, Inc., Chicago, IL, USA) was used for the analyses. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Demographic findings

The positive rate of HPV DNA in the specimens was 5% [4 men (5.7%) and 1 woman (3.3%)], which indicated no significant difference (P=1.000) between genders for HPV infection.

 Genotype findings and clinicopathological factors

Gel electrophoresis results for HPV and high-risk HPV types obtained using specific primer amplification are shown in Figs. 1 and 2, respectively. HPV-16, −18 and −45 were detected in 5 (5%) of the HPV-positive samples (Table II). The 100 samples were classified into three groups based on the pathological diagnosis: 88 Samples were gastric adenocarcinoma, 9 were gastric lymphoma and 3 were gastric and esophagus adenocarcinoma (Table III). Based on the location of the tumor there were three groups of samples: 35 Samples were from the cardia, 62 samples were from the body of the stomach, and three samples were from the lower third of the esophagus and upper stomach. The HPV infection was identified in different anatomical locations of the stomach as follows: Two (40%) cases were positive in the cardiac region, one (20%) case was positive in the body of the stomach and two (40%) cases of patients whose upper stomach and lower esophagus were also involved were positive for HPV DNA. The rate of infection with HPV in patients with gastric cancer who were smokers was 6.3%, and there was a significant association of HPV infection with tumor location, tumor histology and metastasis (Table IV).

 Discussion

In the present study, the rate of HPV infection in 70 males and 30 females was 5.7 and 3.3%, respectively. No significant association was found between gender and HPV infection. HPV DNA was identified in 5% of tumor tissue samples using GP5+/GP6+ consensus primers. HPV-positive DNA samples were further typed and HPV-16, −18 and −45 were identified.

In previous studies from China, differing results were obtained. Koshiol et al (18) proposed that the gastric cardiac region is not a target for HPV-induced carcinogenesis. However, HPV-16 was the most common type identified in the upper digestive tract in a study reported by Xu et al (7). In addition, Yuan et al (19) did not detect HPV in gastric cancer in China. Erol et al (20) investigated 106 gastric cancer samples and identified HPV DNA in 33 cases. The difference in the results among studies indicates the requirement for further investigations. In the present study, based on pathological diagnosis, HPV infection was observed in gastric adenocarcinoma (3%), and in gastric and esophagus adenocarcinoma together (2%). All gastric lymphomas were negative. Based on the anatomical site of the tumor, the rates of HPV infection were 40% in the cardiac region, 20% in the body of stomach and 40% in the upper stomach and lower third of esophagus. To the best of our knowledge, categorization based on anatomical sites, has not been conducted previously. Three cases in the present study were patients who presented with esophagus and gastric adenocarcinoma, and with adenocarcinoma of the lower third of the esophagus and the upper stomach together. According to our results, the HPV-positive percentage in these cases was higher. In conclusion, the question remains as to whether the infection of gastric cancer samples is affecting virus migration from the esophagus to the stomach. Few studies have been conducted on this topic globally, and the existing results are not conclusive. Furthermore, the association between HPV and gastric cancer cannot be confirmed with the present results and further investigations are required.

 Acknowledgements

The present study was supported by the Vice-Chancellor for research of Mazandaran University of Medical Sciences (grant no. 90–96). The authors would like to thank the co-workers of the research groups in the Faculty of Medicine.

 References KonturekPCKonturekSJBrzozowskiTGastric cancer and Helicobacter pylori infectionJ Physiol Pharmacol57Suppl 35165200617033105 SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin64929201410.3322/caac.2120824399786 No authors listed: Surveillance, epidemiology, and end results: Incidence and mortality data, 1973–77Natl Cancer Inst Monogr571108219817278951 CuradoMPEdwardsBShinHRStormHFerlayJHeanueMBoylePCancer incidence in five continentsIXIARCLyon2007 MalekzadehRDerakhshanMHMalekzadehZGastric cancer in Iran: Epidemiology and risk factorsArch Iran Med12576583200919877751 BackertSSchwarzTMiehlkeSKirschCSommerCKwokTGerhardMGoebelUBLehnNKoenigWFunctional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancerInfect Immun7210431056200410.1128/IAI.72.2.1043-1056.200414742552 XuWGZhangLJLuZMLiJYKeYXuGWDetection of human papillomavirus type 16 E6 mRNA in carcinomas of upper digestive tractZhonghua Yi Xue Za Zhi83191019142003(In Chinese)14642078 CorreaPHaenszelWCuelloCTannenbaumSArcherMA model for gastric cancer epidemiologyLancet25860197510.1016/S0140-6736(75)90498-549653 UemuraNOkamotoSYamamotoSMatsumuraNYamaguchiSYamakidoMTaniyamaKSasakiNSchlemperRJHelicobacter pylori infection and the development of gastric cancerN Engl J Med345784789200110.1056/NEJMoa00199911556297 MüngerKBaldwinAEdwardsKMHayakawaHNguyenCLOwensMGraceMHuhKMechanisms of human papillomavirus-induced oncogenesisJ Virol781145111460200410.1128/JVI.78.21.11451-11460.200415479788 WalboomersJMJacobsMVManosMMBoschFXKummerJAShahKVSnijdersPJPetoJMeijerCJMuñozNHuman papillomavirus is a necessary cause of invasive cervical cancer worldwideJ Pathol1891219199910.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F10451482 MuñozNBoschFXde SanjoséSHerreroRCastellsaguéXShahKVSnijdersPJMeijerCJInternational Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancerN Engl J Med348518527200310.1056/NEJMoa02164112571259 de VilliersEMFauquetCBrokerTRBernardHUzur HausenHClassification of papillomavirusesVirology3241727200410.1016/j.virol.2004.03.03315183049 CañadasMPBoschFXJunqueraMLEjarqueMFontROrdoñezEde SanjoséSConcordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk populationJ Clin Microbiol4213301332200410.1128/JCM.42.3.1330-1332.200415004111 de SanjoséSPalefskyJCervical and anal HPV infections in HIV positive women and menVirus Res89201211200210.1016/S0168-1702(02)00189-212445660 GillisonMLKochWMCaponeRBSpaffordMWestraWHWuLZahurakMLDanielRWViglioneMSymerDEEvidence for a causal association between human papillomavirus and a subset of head and neck cancersJ Natl Cancer Inst92709720200010.1093/jnci/92.9.70910793107 MohebbiMMahmoodiMWolfeRNourijelyaniKMohammadKZeraatiHFotouhiAGeographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: Spatial analysis of cancer registry dataBMC Cancer8137200810.1186/1471-2407-8-13718479519 KoshiolJWeiWQKreimerARRenJSGravittPChenWKimEAbnetCCZhangYKamangarFThe gastric cardia is not a target for human papillomavirus-induced carcinogenesisCancer Epidemiol Biomarkers Prev1911371139201010.1158/1055-9965.EPI-10-008920332262 YuanXYWangMYWangXYChangAYLiJNon-detection of Epstein-Barr virus and Human Papillomavirus in a region of high gastric cancer risk indicates a lack of a role for these viruses in gastric carcinomasGenet Mol Biol36183184201310.1590/S1415-4757201300500001823885199 ErolDBulutYYüceHOzercanIHInvestigation of the presence of human papillomavirus DNA in various gastrointestinal carcinoma samplesMikrobiyol Bul432592682009(In Turkish)19621611

Gel electrophoresis pattern of HPV using specific primer amplification. (A) Lane M, DNA ladder (100 bp); lane PC, human DNA (450 bp); lanes 1–4, positive clinical samples of DNA extraction (450 bp); lane 5, negative sample. (B) Lane M, DNA ladder (100 bp); lane 1, HPV DNA (PC; 150 bp); lanes 2 and 4–6, positive clinical samples of HPV (150 bp); lane 3, negative sample. HPV, human papillomavirus; PC, positive control.

Gel electrophoresis pattern of high-risk HPV types using specific primer amplification. Lane M, DNA ladder (100 bp); lane 1, DNA HPV type 45 (PC; 475 bp); lane 2, positive sample DNA HPV type 45 (475 bp); lane 3, positive sample DNA HPV type 16 (325 bp); lanes 4 and 5, negative control; lane 6, DNA HPV type 18 (PC; 425 bp); lane 7, positive sample DNA HPV type 18 (425 bp). HPV, human papillomavirus; PC, positive control.

Primer sequences.

Primer Sequence (5′ to 3′)
GP5+ TTTGTTACTGTGGTAGATACTAC
GP6+ GAAAAATAAACTGTAAATCATATT
β-actin (forward) CTGCCGTTTTGCGTAGGAC
β-actin (reverse) AGGCGTACAGGGATAGCAC

Association between virus genotypes and anatomical site of the tumor.

Human papillomavirus genotype Cardia, n (%) Body of stomach, n (%) Upper stomach and lower third of esophagus, n (%) Total, n (%)
16 2 (40) – 1 (20) 3 (60)
18 – 1 (20) – 1 (20)
45 – – 1 (20) 1 (20)
Total 2 (40) 1 (20) 2 (40)   5 (100)

Frequency of HPV infection based on pathological diagnosis.

HPV infection Gastric adenocarcinoma Gastric lymphoma Gastric and esophageal adenocarcinoma Total
Yes   3 0 2     5
No 85 9 1   95
Total 88 9 3 100

HPV, human papillomavirus.

Association between HPV infection and clinicopathological and demographic factors in patients.

Factor Total, n (%) HPV-negative, n (%) HPV-positive, n (%) P-value (χ2 or Fisher's exact test)
Gender   1.000
  Male 70 (70) 66/70 (94.3) 4/70 (5.7)
  Female 30 (30) 29/30 (96.7) 1/30 (3.3)
Location of tumor <0.001
  Cardia 35 (35) 33/35 (94.3) 2/35 (5.7)
  Body of stomach 62 (62) 61/62 (98.4) 1/62 (1.6)
  Lower third of esophagus and upper stomach 3 (3) 1/3 (33.3) 2/3 (66.7)
Histology <0.001
  Gastric adenocarcinoma 88 (88) 85/88 (96.6) 3/88 (3.4)
  Gastric lymphoma 9 (9) 9/9 (100.0) 0/9 (0.0)
  Esophagus and gastric adenocarcinoma 3 (3) 1/3 (33.3) 2/3 (66.7)
Weight   0.583
  Weight loss 78 (78) 73/78 (93.6) 5/78 (6.4)
  No weight loss 22 (22) 22/22 (100.0) 0/22 (0.0)
Smoking   0.669
  Smoker 48 (48) 45/48 (93.8) 3/48 (6.3)
  Non smoker 52 (52) 50/52 (96.2) 2/52 (3.8)
Alcohol usage   1.000
  Alcohol use 16 (16) 15/16 (93.8) 1/16 (6.3)
  No alcohol use 84 (84) 80/84 (95.2) 4/84 (4.8)
Family history of gastric cancer   0.068
  Yes 57 (57) 52/57 (91.2) 5/57 (8.8)
  No 43 (43) 43/43 (100) 0/43 (0.0)
Metastasis   0.007
  Positive 38 (38) 33/38 (86.8)   5/38 (13.2)
  Negative 62 (62)   62/62 (100.0) 0/62 (0.0)

HPV, human papillomavirus.